Parent-Child Interaction Therapy for Disruptive Behaviors
(RAINBOW Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to understand and treat behavior problems in young children with tuberous sclerosis complex (TSC), a genetic disorder. It tests an internet-based therapy called Parent-Child Interaction Therapy (PCIT), which helps parents manage their children's challenging behaviors. Some children will start the therapy immediately, while others will begin after a 6-month delay, but all will eventually receive the same care. Children aged 3 to 6 years with TSC who face behavior challenges at home and have a parent available for therapy sessions might be a good fit for this study. As an unphased trial, this study offers families the chance to access innovative therapy that could significantly improve their child's behavior.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It seems focused on behavioral therapy, so it's likely you can continue your medications, but you should confirm with the study team.
What prior data suggests that Parent-Child Interaction Therapy (PCIT) is safe for children with TSC?
Research shows that Parent-Child Interaction Therapy (PCIT) is generally safe and well-tolerated. Studies have demonstrated that PCIT effectively reduces challenging behaviors in children. For instance, one study reported significant improvements in children's behavior and a decrease in parenting stress. These positive results suggest that PCIT works well without needing major changes for different groups.
Additionally, PCIT has succeeded in various settings, including with children in foster care. This widespread success indicates its safety and effectiveness. While this study phase does not provide specific safety data, the use of PCIT with different groups supports its safety for children with behavior issues.12345Why are researchers excited about this trial?
Parent-Child Interaction Therapy (PCIT) is unique because it focuses on improving the parent-child relationship as a means to address disruptive behaviors. Unlike typical treatments that may rely on medication or individual therapy for the child, PCIT involves both the parent and child in real-time coaching sessions to enhance their communication and interaction skills. Researchers are excited about this approach because it empowers parents with effective tools and strategies to manage challenging behaviors, potentially leading to long-lasting positive changes in the family dynamic. This therapy not only targets the child's behavior but also strengthens the emotional bond between parent and child, which can be crucial for sustained behavioral improvement.
What evidence suggests that Parent-Child Interaction Therapy might be an effective treatment for behavior problems in children with TSC?
Studies have shown that Parent-Child Interaction Therapy (PCIT) reduces disruptive behaviors in children. Research indicates significant improvement in children's behavior problems, with parents noticing fewer issues after completing the therapy. One study found that all groups using PCIT experienced better child behavior and improved parenting skills. Another analysis showed that PCIT leads to important changes that last over time. In this trial, participants will either receive immediate PCIT treatment or be placed on a waitlist control, receiving PCIT after a delay. Although PCIT hasn't been specifically studied for children with tuberous sclerosis complex (TSC), its success with other disruptive behavior disorders suggests it could also help with TSC-related behavior issues.16789
Who Is on the Research Team?
Nicole McDonald, PhD
Principal Investigator
University of California, Los Angeles
Are You a Good Fit for This Trial?
This trial is for children aged 3-6 with tuberous sclerosis complex (TSC), both with and without behavior problems. To participate, kids must have a diagnosis of TSC. The study aims to help those struggling with disruptive behaviors by using internet-based therapy tailored for TSC families.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Initial assessments of developmental abilities and behavior problems using parent report measures and video recordings
Treatment
Internet-based Parent-Child Interaction Therapy (PCIT) sessions conducted weekly
Follow-up
Participants are monitored for safety and effectiveness after treatment, including play interactions, parent interviews, and questionnaires
What Are the Treatments Tested in This Trial?
Interventions
- Parent-Child Interaction Therapy (PCIT)
Trial Overview
The RAINBOW study tests an adapted version of Parent-Child Interaction Therapy (PCIT) delivered online to manage challenging behaviors in young children with TSC. Participants are randomly chosen to start treatment immediately or after a six-month wait, but all will receive the same therapy sessions weekly for up to 20 weeks.
How Is the Trial Designed?
Participants randomized to the immediate treatment condition will receive written and verbal feedback after the baseline assessment visit. These families will begin PCIT shortly after this visit. These families will participate in follow-up visits at 3 and 6 months after the baseline visit.
Participants randomized to the waitlist control (or delayed treatment) condition will receive written and verbal feedback after the baseline assessment visit. These families will participate in follow-up visits at 3 months, 6 months, and 12 months after the baseline visit. They will receive the same treatment (PCIT) after the 6-month assessment.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Los Angeles
Lead Sponsor
Published Research Related to This Trial
Citations
Parent–Child Interaction Therapy for Disruptive Behavior
Research studies demonstrate that PCIT is effective across a variety of DBP conditions, showing significant reductions in child behavioral problems and ...
Parent–Child Interaction Therapy: current perspectives - PMC
Results have indicated decreased child disruptive behavior problems on the Eyberg Child Behavior Inventory (ECBI) at posttreatment. High rates (100%) of child ...
Understanding parent-child interaction therapy outcomes ...
All groups demonstrated significant improvements in caregiver-reported child disruptive behaviors and observed positive parenting skills from ...
Treatment Outcomes | Parent Child Interaction Therapy
Benefits include clinically significant improvements on multiple measures of disruptive behavior and strong maintenance data, suggesting the PCIT is an ...
Meta-analysis of the Efficacy and Effectiveness of Parent ...
Parent-Child Interaction Therapy (PCIT) is a behavioural therapy that is an alternative to classical intervention for children with behavioural problems and ...
Randomized Trial of Parent–Child Interaction Therapy ...
This randomized trial presents the first evidence that PCIT improves inhibitory control and emotion regulation in a child welfare parents.
Outcomes of Parent-Child Interaction Therapy (PCIT) for ...
Treatment outcomes include lower parenting stress, reduced recidivism of abuse, decreased problematic child behaviors, and improved caregiver mental health ( ...
Parent-Child Interaction Therapy: A Meta-analysis
Meta-analyses from PCIT studies reveal that robust positive outcomes and content modification may not be necessary for diverse populations.
Parent-child interaction therapy for children in foster care ...
Results demonstrate that PCIT can be similarly effective in reducing problematic behaviors for children placed in foster care when compared to children not in ...
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.